Phio Pharmaceuticals Corp

Phio Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company that develops immuno-oncology therapeutics in the United States. Its lead candidate, PH-762, is an INTASYL compound designed to reduce PD-1 expression and is being evaluated in a multi-center Phase 1b dose-escalation trial. Another candidate, PH-894, is an INTASYL compound intended to silence BRD4, a protein that controls gene expression in T cells and tumor cells, and is in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Founded in 2003, it is based in King of Prussia, Pennsylvania.